C83.57
Lymphoblastic (diffuse) lymphoma, spleen
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphoblastic (diffuse) lymphoma of the spleen is a rare type of non-Hodgkin lymphoma characterized by the abnormal growth of lymphoblasts, which are immature lymphatic cells. This disease primarily affects the spleen, an organ involved in blood filtration and immune response. Recognizing and understanding this condition is crucial for timely diagnosis and management, although it requires specialized medical evaluation and treatment.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal lymphocyte growth Immunodeficiency conditions that weaken immune defenses Previous exposure to radiation or certain chemotherapy agents Infections with viruses such as Epstein-Barr virus (EBV) or human T-lymphotropic virus (HTLV-1)
Key Symptoms: Enlarged spleen causing abdominal discomfort or fullness Unexplained weight loss Persistent fever and night sweats Fatigue and weakness Generalized lymphadenopathy (swollen lymph nodes) Frequent infections due to compromised immune system
Diagnostic & Treatment
Diagnosis Path: Diagnosing lymphoblastic lymphoma of the spleen typically involves a combination of clinical evaluation and laboratory tests. Imaging studies such as ultrasound, CT scans, or MRI may reveal an enlarged spleen and associated lymph node involvement. A definitive diagnosis is often made through a biopsy of affected tissues, followed by microscopic examination and immunophenotyping to identify lymphoma cell types. Additional tests may include bone marrow biopsies, blood tests, and molecular studies to assess disease extent and guide treatment planning.
Treatment Protocols: The treatment approach for lymphoblastic lymphoma of the spleen usually involves intensive chemotherapy protocols tailored to this aggressive lymphoma type. In some cases, targeted therapy or immunotherapy may be considered, especially if specific genetic markers are present. For eligible patients, stem cell transplantation might be an option to achieve long-term remission. Supportive care addressing symptoms and preventing infections is also important throughout treatment. Regular follow-up and monitoring are essential to assess response and manage any potential complications.
Clinical Advice & FAQs
Billing Guidance
Is C83.57 a billable ICD-10 code?
Yes, C83.57 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.57?
Clinical documentation must specify the nature of Lymphoblastic (diffuse) lymphoma, spleen and any associated comorbidities for accurate reporting.
Cite this Clinical Reference